Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5925730 | FERRING | GnRH antagonists |
May, 2021
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10973870 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
US9579359 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
US10729739 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
US11766468 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
US11826397 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) | |
US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(7 years from now) |
Firmagon is owned by Ferring.
Firmagon contains Degarelix Acetate.
Firmagon has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Firmagon are:
Firmagon was authorised for market use on 24 December, 2008.
Firmagon is available in powder;subcutaneous dosage forms.
Firmagon can be used as method of treating prostate cancer, treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect, gnrh antagonist indicated for treatment of patients with advanced prostate cancer.
Drug patent challenges can be filed against Firmagon from 24 December, 2012.
The generics of Firmagon are possible to be released after 27 April, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer; Gnrh antagonist indicated for trea...
Dosage: POWDER;SUBCUTANEOUS